Royalty Pharma plc (NASDAQ:RPRX) is heavily dominated by
institutional shareholders who own 70% of the company. Notable investments include
Principal Financial Group Inc. with a $956,000 position, and
New Century Financial Group LLC with a $1.09 million investment. The biotech firm has recently entered several deals, most notably selling a share of its heart drug to
Cytokinetics for up to $575 million - a move that has frustrated investors and caused Cytokinetics' stock to fall 10%. Royalty Pharma plc's recent Q1 performance was solid, beating earnings and revenue estimates, leading many to view it as a compelling stock investment. The company's robust financial performance and strategic dealings, including cashing on a cancer drug with a $905M deal with Agios, paint a positive picture, but the complexity of some deals has raised concerns. At a low of $25.84 the company is being closely watched by analysts who anticipate the market will correct the share price. Meanwhile, future expectations indicate a rise in full-year earnings by 2023.
Royalty Pharma Stocks News Analytics from Sat, 08 Jul 2017 07:00:00 GMT to Sat, 06 Jul 2024 11:56:52 GMT -
Innovation -2
- Information 8
- Rumor -6
